Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Advisory Committee Wants FDA-Defined Standards Before Clearing Abuse-Deterrent Stimulant Label

Executive Summary

Panel on Arbor Pharmaceuticals' reformulated stimulant highlights the risks of trying to craft a new labeling niche without any FDA guidance or endorsement of the idea.

You may also be interested in...



US COVID-19 Advisors Vexed By Vaccine Post-EUA Placebo Controls, But Agree On Need

FDA indicates it expects sponsors and other government agencies to come up with ways to fulfill its request for placebo-controlled studies post-emergency use authorization of COVID-19 vaccines, but neither it nor vaccines advisory committee see a clear way to do this. 

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.

COVID-19 Vaccine Sponsors Want US FDA To Find Alternatives For Control-Arm Data After First EUA

US FDA must rethink guidance on maintaining placebo-control in COVID-19 trials after any vaccine gets an EUA, companies say, arguing current proposal may not be ethical or feasible. Disease organizations who agree with the hurdles to preserving placebo-control maintain this is a reason why any EUA must meet a very high standard.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel